Heart News and Research

RSS

Researchers discover circadian rhythms regulate fat metabolism

UC Irvine researchers have discovered that circadian rhythms the internal body clock regulate fat metabolism. This helps explain why people burn fat more efficiently at certain times of day and could lead to new pharmaceuticals for obesity, diabetes and energy-related illnesses.

16 Nov 2010

New stem cell-infused patch improves heart function after myocardial infarction

University of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.

16 Nov 2010

Iron in plaque may predict risk of myocardial infarction

Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.

16 Nov 2010

Study finds significant variability in CPR quality between day and night

CPR quality is worse during in-hospital cardiac arrests occurring overnight than those that happen during the day, according to a new University of Pennsylvania School of Medicine study that will be presented at the American Heart Association's annual Scientific Sessions on November 14.

16 Nov 2010

New high-sensitive blood test may help predict risk of heart failure in older people

Researchers at the University of Maryland School of Medicine in Baltimore report that a new, highly sensitive investigative blood test may help predict the risk of heart failure and cardiovascular death much earlier than previously possible in older people who do not have symptoms of heart failure.

16 Nov 2010

Reducing salt intake can enhance health of young adults in future: Research

Cutting back on salt in teenagers' diets by as little as one-half teaspoon, or three grams, a day, could reduce the number of young adults with high blood pressure by 44 to 63 percent, according to new research presented Sunday, Nov. 14 at the American Heart Association's Scientific Sessions 2010 meeting in Chicago.

16 Nov 2010

St. Jude presents results from ASSERT trial for stroke at American Heart Association

St. Jude Medical, Inc., a global medical device company, today announced the results of the ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (ASSERT), a St. Jude Medical sponsored trial conducted by the Population Health Research Institute of McMaster University and Hamilton Health Sciences in Hamilton, Canada.

16 Nov 2010

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

16 Nov 2010

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

16 Nov 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Certain measures of the blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using a highly sensitive test, are associated with the development of heart failure or cardiovascular death in older adults, according to a study that will appear in the December 8 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

16 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

diaDexus third quarter revenue increases 26% to $3.2 million

diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced financial results for the third quarter of 2010.

15 Nov 2010

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association’s annual conference in Chicago showing that the company’s proprietary “off-the-shelf” stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

15 Nov 2010

Erroneous defibrillators: FDA new initiative to check safety

More problems are being reported in external defibrillators, the life-saving medical devices located in emergency rooms, airports and other public places. These Automated external defibrillators, or AEDs are generally used in patients who have suffered sudden cardiac arrest if used in the first few minutes after their collapse. They deliver electrical energy to the heart to restore its normal rhythm.

15 Nov 2010

Emerging blood thinners to prevent stroke

As blood thinners emerge in the market for stroke prevention many experts believe is still too early to predict how they will stack up in the $15 billion a year market.

15 Nov 2010

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

Although some data have suggested that omega-3 fatty acid supplements, such as from fish oil, may improve treatment of atrial fibrillation, a randomized trial with more than 600 patients finds that treatment with high-dose prescription omega-3 did not reduce the recurrence of atrial fibrillation over six months, according to a study that will appear in the December 1 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

Heart News and Research

Researchers discover circadian rhythms regulate fat metabolism

New stem cell-infused patch improves heart function after myocardial infarction

Iron in plaque may predict risk of myocardial infarction

Study finds significant variability in CPR quality between day and night

New high-sensitive blood test may help predict risk of heart failure in older people

Reducing salt intake can enhance health of young adults in future: Research

St. Jude presents results from ASSERT trial for stroke at American Heart Association

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

diaDexus third quarter revenue increases 26% to $3.2 million

Novel heart attack treatment results presented at premier USA cardiology forum

Erroneous defibrillators: FDA new initiative to check safety

Emerging blood thinners to prevent stroke

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News